tienan feng

Prof. tienan feng


Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 January 2020 in International Journal of Genomics
Verified
Journal Article
Open access
PDF file
LLLei Li
Lei Li
TFtienan feng
tienan feng
WZWeituo Zhang
Weituo Zhang
SGSumeng Gao
Sumeng Gao
RWRuoyang Wang
Ruoyang Wang
BQBiyun Qian
Biyun Qian
Background. Lung cancer is one of the leading diagnosed cancers worldwide, and microRNAs could be used as biomarkers to diagnose lung cancer. hsa-miR-195 has been demonstrated to affect the prognosis of NSCLC (non-small-cell lung cancer) in a previous study. However, the diagnostic value of hsa-miR-195-5p in lung cancer has not been investigated. Methods. To evaluate the ability of hsa-miR-195-5p to diagnose lung cancer, we compared the expression of hsa-miR-195-5p in lung cancer patients, COPD patients, and normal controls. Receiver operating characteristic (ROC) curve analysis was performed to investigate the sensitivity and specificity of hsa-miR-195-5p. Coexpression network and pathway analysis were carried out to explore the mechanism. Results. We found that hsa-miR-195-5p had lower expression in lung cancer and COPD patients than in normal controls, and the AUC was 0.92 for diagnosing lung cancer. hsa-miR-143 correlated with hsa-miR-195-5p, and by combining these two microRNAs, the AUC was 0.97 for diagnosing lung cancer. Conclusions. hsa-miR-195-5p may act as a biomarker that contributes to the diagnosis of lung cancer and the detection of its high-risk population.

30 June 2013 in Natural Hazards
Verified
Journal Article
Closed access
PDF file
TFtienan feng
tienan feng
Zhonghua HongZhonghua Hong
Zhonghua Hong
HWHengjing Wu
Hengjing Wu
QFQiushi Fu
Qiushi Fu
CWChaoxin Wang
Chaoxin Wang
XTXiaohua Tong
Xiaohua Tong

6 September 2019 in BMC Infectious Diseases
Verified
Journal Article
Open access
PDF file
ZZZhigang Zhou
Zhigang Zhou
TFtienan feng
tienan feng
YXYun Xie
Yun Xie
PHPeijie Huang
Peijie Huang
HXHui Xie
Hui Xie
RWRuilan Wang
Ruilan Wang
Sepsis is still a common critical disease with high morbidity and mortality in intensive care unit. Despite published guidelines for sepsis, development of antibiotic therapy and advanced organ support technologies, the mortality of sepsis patients is still 25% or more. It is necessary to distinguish the subtypes of sepsis, and the targeted therapy for the patients need to be explored. Platelets have various biological functions in hemostasis and thrombosis, host defense, inflammatory/immune responses and tissue repair/regeneration. Moreover, severe thrombocytopenia or sustained thrombocytopenia was closely associated with multiply organ dysfunction and higher mortality in sepsis patients. The clinical therapies for thrombocytopenia are platelet transfusion and platelet-elevating drugs. However, platelet transfusion has many defects in clinical practice in sepsis patients, and the impact of platelet-elevating drugs for sepsis patients is still unclear. RESCUE trial is aim to explore the effect of a platelet-elevating drug, recombinant human thrombopoietin (rhTPO), as an effective rescue therapy on sepsis patients with acute severe thrombocytopenia. It is a randomized, open-label, multi-center, controlled trial in 5 tertiary academic hospitals including medical, surgical or general ICUs. In this study, a total of 200 sepsis patients with severe thrombocytopenia will be randomly assigned in a 1:1 ratio to the control and rhTPO group. The patients will be followed up to 28 days after randomization. All patients in two groups receive the same treatment based on the guideline of Surviving Sepsis Campaign. Primary outcome is 28-day mortality. Secondary outcomes are the changes of PCs, blood transfusion, biomarkers of infection and organ function, days free from advanced organ support, drug-related adverse events, the length of ICU and hospital stay. RESCUE trial is the first randomized controlled trial to explore the impact of rhTPO for severe thrombocytopenia in sepsis patients diagnosed by sepsis-3.0 standard. Furthermore, RESCUE trial results will be of significant clinical value on the targeted therapy and add clinical evidence that rhTPO is an effective rescue therapy for these sepsis patients. ClinicalTrials.gov : NCT02707497. Registered Date: March 3rd, 2016. Protocol Version 3. Protocol Date: January 25th, 2019.

10 June 2020 in BMC Public Health
Verified
Journal Article
Open access
PDF file
YLYao Li
Yao Li
MPMiao Pu
Miao Pu
YWYaping Wang
Yaping Wang
TFtienan feng
tienan feng
CJChenghua Jiang
Chenghua Jiang
Background: Injuries are of growing public health concern in China, and the trends of urban-rural injury mortality disparity for the last decade are still being explored. This study aims to analyze trends in injury mortality disparity between urban and rural areas of China by region, sex, and age from 2010 to 2016. Methods: Using data from the Disease Surveillance Points system (DSPs) collected by the Chinese Center for Disease Control and Prevention (CDC) from 2010 to 2016, injury age-standardized mortality rates (ASMRs) and rate ratios (RRs) were calculated for different groups. Chi-square tests were used to compare differences in rates between urban and rural residents. The time trends of injury ASMRs were assessed via the annual percentage change (APC), and RRs were used to analyze urban-rural mortality disparity. Results: The crude injury mortality rate of rural areas was 1.5 times higher than that of urban areas. The urban-rural RR of injury ASMR decreased from 1.8 to 1.5 (APC = 5.0%) over time, from 2.0 to 1.7 (APC = 4.7%) for eastern regions, from 1.9 to 1.5 (APC = 5.4%) and from 1.6 to 1.3 (APC = 4.5%) among males and females, respectively. Further decreases were from 2.0 to 1.4 (APC = 7.8%), from 1.9 to 1.6 (APC = 6.4%), and from 1.8 to 1.2 (APC = 5.7%) in the 5–14, 45–64, and 65+ year age groups, respectively. The urban-rural RRs of ASMRs for fall, drowning and suicide decreased from 1.3 to 1.2 (APC = − 3.0%), from 2.3 to 1.6 (APC = − 13.8%) and from 2.1 to 1.6 (APC = − 9.9%,), respectively. Conclusions: The urban-rural injury mortality disparity was large, but showed a significant decreasing trend in China. Residents of eastern regions, males/females, 5–14/45+ year age groups in the urban-rural injury mortality disparity all decreased gradually during the investigated period.

26 July 2024 in European Thyroid Journal
Verified
Journal Article
Open access
PDF file
HZHaiyang Zhang
Haiyang Zhang
SWShuo Wu
Shuo Wu
SHShuyu Hu
Shuyu Hu
XFXianqun Fan
Xianqun Fan
XSXuefei Song
Xuefei Song
HZHuifang Zhou
Huifang Zhou
Background: Thyroid eye disease (TED) is an autoimmune orbital disease, with intravenous glucocorticoid (IVGC) therapy as the first-line treatment. Due to uncertain response rates and possible side effects, various prediction models have been developed to predict IVGC therapy outcomes. Methods: A thorough search was conducted in PubMed, Embase, and Web of Science databases. Data extraction included publication details, prediction model content, and performance. Statistical analysis was performed using R software, including heterogeneity evaluation, publication bias, subgroup analysis, and sensitivity analysis. Forest plots were utilized for result visualization. Results: Of the 12 eligible studies, 47 prediction models were extracted. All included studies exhibited a low-to-moderate risk of bias. The pooled area under the receiver operating characteristic curve (AUC) and the combined sensitivity and specificity for the models were 0.81, 0.75, and 0.79, respectively. In view of heterogeneity, multiple meta-regression and subgroup analysis were conducted, which showed that marker and modeling types may be the possible causes of heterogeneity (P < 0.001). Notably, imaging metrics alone (AUC = 0.81) or clinical characteristics combined with other markers (AUC = 0.87), incorporating with multivariate regression (AUC = 0.84) or radiomics analysis (AUC = 0.91), yielded robust and reliable prediction outcomes. Conclusion: This meta-analysis comprehensively reviews the predictive models for IVGC therapy response in TED. It underscores that integrating clinical characteristics with laboratory or imaging indicators and employing advanced techniques like multivariate regression or radiomics analysis significantly enhance the efficacy of prediction. Our research findings offer valuable insights that can guide future studies on prediction models for IVGC therapy in TED.

28 July 2020 in Food & Function
Verified
Journal Article
Closed access
PDF file
TFtienan feng
tienan feng
QZQi Zhang
Qi Zhang
QLQiang Li
Qiang Li
TZTengteng Zhu
Tengteng Zhu
WLWenwen Lv
Wenwen Lv
BQBiyun Qian
Biyun Qian
D-Limonene, a type of natural extract obtained from citrus oils, was reported to have anti-cancer effects and be well-tolerated by cancer patients. Despite arousing interest as a cancer chemopreventive substance, the transcriptomic profile of D-limonene in humans is poorly understood. Based on the results of the transcriptomic profiling, a lncRNA named protein disulfide isomerase family A member three pseudogene (PDIA3P1) was found to be regulated by D-limonene. PDIA3P1 is an oncogene verified by three lung adenocarcinoma (LUAD) datasets. The knockdown of PDIA3P1 with siRNA decreased the viability, invasion, migration, and proliferation of LUAD cells. Based on The Cancer Genome Atlas (TCGA) LUAD datasets, PDIA3P1 regulates functions and pathways mainly including lipid metabolism, immunity, and the change of the chromosome structure. This study comprehensively performs the transcriptomic analysis of the D-limonene regulation on LUAD, and reveals that PDIA3P1 may be the mediator in helping D-limonene to prevent and suppress LUAD via lipid metabolism, immunity pathway, and the change in the chromosome structure.